Delveinsight

AUGUST 2, 2020

The company has also signed a licensing agreement with Ono Pharmaceutical , a Japanese pharma company, transferring exclusive rights to develop and commercialise anamorelin in Japan, South Korea, and Taiwan. Cancer Cachexia Pipeline. Apart from the products as mentioned earlier, Tetra Bio?

Marketing 94

Marketing Pharma Companies Development Hormones 94

pharmaphorum

APRIL 28, 2022

Although they have, by definition, small addressable markets, the treatments cost just as many resources to develop as therapies for more common diseases – sometimes more, because of the added difficulty of finding sufficiently large patient populations for trials and finding disease experts to run them. How big pharma tackles rare diseases.

Pharma Companies 57

Pharma Companies Branding Development Marketing 57

pharmaphorum

SEPTEMBER 8, 2022

It is a similar approach to that of another form of oncology treatment that is also experiencing a surge of interest, antibody-drug conjugates (ADCs). The company stated that there was “no indication of risk,” but it meant that the rollout and the clinical development of Pluvicto was hampered.

Manufacturing 102

Manufacturing Development Drugs Antibody 102

pharmaphorum

MARCH 9, 2021

Last year, Belgium’s ExeVir Bio raised 23 million euros ($27 million) to finance development of llama antibodies – and now it is ready to begin clinical development of a potential treatment that could be effective against emerging COVID-19 variants. Ablynx, which is now a subsidiary of Sanofi following a $4.8

Antibody 98

Antibody Life Science Scientist Vaccination 98

Drug Discovery World

OCTOBER 16, 2023

Alchemab, on the other hand, has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires, drawing from the expertise in Cambridge to progress the company’s mission to build a broad pipeline of protective therapeutics for hard-to-treat diseases.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

The Pharma Data

DECEMBER 17, 2020

Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs. Prior to Fulcrum, Cadavid held several leadership positions at Biogen, including Senior Medical Director of the multiple sclerosis clinical development group.

Development 52

Development Gene Therapy Engineer Life Science 52

pharmaphorum

DECEMBER 23, 2020

Pharma companies have also made headway in rare diseases as several pipeline projects came to fruition. This is a rare disease that affects the kidney but is caused by overproduction of antibodies produced in the lining of the small intestine, for which there are no approved medications. Rare disease progress.

Marketing 77

Marketing Gene Silencing Gene Drugs 77

pharmaphorum

MAY 14, 2021

This and its smaller size – it’s a “nanobody” that is only a fraction of the size of conventional antibodies – could allow it to penetrate deeper into the skin and joints. It’s extremely possible a pharma company may want to partner and it can have many forms. is the future in inflammatory diseases.”.

Licensing 59

Licensing Licensing Drugs Marketing 59

Delveinsight

AUGUST 17, 2020

million in 2019 and is anticipated to increase at a CAGR for the study period 2017-2030 owing to dynamic pipeline therapies in the mid-/ late-stage clinical development and rising gastroparesis prevalence. The Gastroparesis market size in the 7MM was found to be USD 3,170.01 FDA for a phase 2b study in diabetic kidney disease (DKD).

Marketing 54

Marketing FDA Approval Trials Clinical Development 54

pharmaphorum

APRIL 19, 2021

The French pharma just signed a deal with C4XD to develop drugs that could lead to oral medicines for inflammatory diseases such as psoriasis, as big pharma looks for more patient-friendly alternatives to therapies based on injections of antibody-based drugs. It spotlighted the UK as a place to do clinical development.

Vaccination 94

Vaccination Vaccine Life Science Antibody 94

pharmaphorum

JANUARY 29, 2021

Lilly is paying $20 million upfront for exclusive rights to AK1780, a P2X7 receptor antagonist in early-stage clinical development for neuroinflammatory pain conditions, outside Japan and China. While tanezumab is an antibody and has to be delivered by subcutaneous injection, AK1780 is orally bioavailable.

Licensing 52

Licensing Licensing Bioavailability Antibody 52

pharmaphorum

NOVEMBER 12, 2020

The mid-sized pharma group has also signed a collaboration with Florida, US-based Lacerta Therapeutics , adding more AAV capsids – well established as a staple for delivering gene therapy sequences – as well as another gene therapy candidate.

Gene Therapy 52

Gene Therapy Gene Manufacturing Contract Manufacturing 52

XTalks

AUGUST 18, 2021

These samples are often made available to support the research efforts of pharma companies developing new antibacterial agents. In addition to drug discovery and development, isolates can also be used in the design and testing of rapid diagnostics tools, and can inform site selection during the clinical trials process.

Development 105

Development Bacteria Drugs Vaccination 105

Delveinsight

NOVEMBER 29, 2020

Key players such as Novartis , Annexin Pharmaceuticals , Gene Signal , Ocular Therapeutics , and Asclepix Therapeutics along with other pharma companies are investigating their candidates proactively in a quest to launch their therapies as soon as possible in the Retinal vein occlusion market.

Marketing 52

Marketing Pharma Companies Drug Delivery Clinical Trials 52

Drug Discovery World

OCTOBER 7, 2022

RA: How can the integration of industry and academia help streamline drug development? . TH : Increasingly, large pharma companies need scale, agility and access to academic partnerships to succeed. It is unsurprising that many pharma companies are increasingly keen to work with academia or academic spin-out.

HR 52

HR Research Drugs Development 52

The Pharma Data

OCTOBER 14, 2020

Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML. VBL is currently advancing its lead anti-MOSPD2 candidate through IND-enabling studies.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52

The Pharma Data

DECEMBER 16, 2020

the company is exploring other ways to combat COVID-19. AstraZeneca is partnering with INOVIO and multiple universities to advance INOVIO’s innovative DNA-encoded monoclonal antibody (dMAb) technology. Recombinant monoclonal antibodies are designed to enhance the immune system’s ability to regulate cell functions.

Vaccination 52

Vaccination Vaccine DNA Antibody 52